Magnetic trapping and Zeeman relaxation of imidogen (NH X-triplet-Sigma)

Imidogen (NH) radicals are magnetically trapped and their Zeeman relaxation and energy transport collision cross sections with helium are measured. Continuous buffer-gas loading of the trap is direct from a room-temperature molecular beam. The Zeeman relaxation (inelastic) cross section of magnetically trapped electronic, vibrational and rotational ground state imidogen in collisions with He-3 is measured to be 3.8 +/- 1.1 E-19 cm^2 at 710 mK. The NH-He energy transport cross section is also measured, indicating a ratio of diffusive to inelastic cross sections of gamma = 7 E4 in agreement with the recent theory of Krems et al. (PRA 68 051401(R) (2003))Comment: 12 pages, 3 figure

Time-Domain Measurement of Spontaneous Vibrational Decay of Magnetically Trapped NH

The v = 1 -> 0 radiative lifetime of NH (X triplet-Sigma-, v=1,N=0) is determined to be tau_rad,exp. = 37.0 +/- 0.5 stat +2.0 / -0.8 sys miliseconds, corresponding to a transition dipole moment of |mu_10| = 0.0540 + 0.0009 / -0.0018 Debye. To achieve the long observation times necessary for direct time-domain measurement, vibrationally excited NH (X triplet-Sigma-, v=1,N=0) radicals are magnetically trapped using helium buffer-gas loading. Simultaneous trapping and lifetime measurement of both the NH(v=1, N=0) and NH(v=0,N=0) populations allows for accurate extraction of tau_rad,exp. Background helium atoms are present during our measurement of tau_rad,exp., and the rate constant for helium atom induced collisional quenching of NH(v=1,N=0) was determined to be k_q < 3.9 * 10^-15 cm^3/s. This bound on k_q yields the quoted systematic uncertainty on tau_rad,exp. Using an ab initio dipole moment function and an RKR potential, we also determine a theoretical value of 36.99 ms for this lifetime, in agreement with our experimental value. Our results provide an independent determination of tau_rad,10, test molecular theory, and furthermore demonstrate the efficacy of buffer-gas loading and trapping in determining metastable radiative and collisional lifetimes.Comment: 10 pages + 3 figures (11 pages total) v2 has minor corrections and explanations accepted for publication in PR

Cold N+NH Collisions in a Magnetic Trap

We present an experimental and theoretical study of atom-molecule collisions in a mixture of cold, trapped atomic nitrogen and NH molecules at a temperature of $\sim 600$~mK. We measure a small N+NH trap loss rate coefficient of $k^{(\mathrm{N+NH})}_\mathrm{loss} = 8(4) \times 10^{-13}$~cm$^{3}$s$^{-1}$. Accurate quantum scattering calculations based on {\it ab initio} interaction potentials are in agreement with experiment and indicate the magnetic dipole interaction to be the dominant loss mechanism. Our theory further indicates the ratio of N+NH elastic to inelastic collisions remains large ($>100$) into the mK regime

Magnetic Trapping of NH Molecules with 20 s Lifetimes

Buffer gas cooling is used to trap NH molecules with 1/e lifetimes exceeding 20 s. Helium vapor generated by laser desorption of a helium film is employed to thermalize 10$^5$ molecules at a temperature of 500 mK in a 3.9 T magnetic trap. Long molecule trapping times are attained through rapid pumpout of residual buffer gas. Molecules experience a helium background gas density below 1×10$^{12}$ cm$^{−3}$.Engineering and Applied SciencesPhysic

Magnetic Trapping of Atomic Nitrogen (14^{14}N) and Cotrapping of NH (XX3^{3}Σ\Sigma -)

We observe magnetic trapping of atomic nitrogen ($^{14}$N) and cotrapping of ground state imidogen ($^{14}$NH, $X$$^{3}$$\Sigma$ -). Both are loaded directly from a room temperature beam via buffer gas cooling. We trap approximately 1 x 10$^{11}$ $^{14}$N atoms at a peak density of 5 x 10$^{11}$ cm$^{-3}$ at 550 mK. The $12\pm{4} s 1/e$ lifetime of atomic nitrogen in the trap is limited by elastic collisions with the helium buffer gas. Cotrapping of $^{14}$N and $^{14}$NH is accomplished, with 10$^{8}$ NH trapped molecules at a peak density of 10$^{8}$ cm$^{-3}$.Physic

Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages

Background: HIV-1 Tat is essential for HIV replication and is also a well-known neurotoxic factor causing HIV-associated neurocognitive disorder (HAND). Currently, combined antiretroviral therapy targeting HIV reverse transcriptase or protease cannot prevent the production of early viral proteins, especially Tat, once HIV infection has been established. HIV-infected macrophages and glial cells in the brain still release Tat into the extracellular space where it can exert direct and indirect neurotoxicity. Therefore, stable production of anti-Tat antibodies in the brain would neutralize HIV-1 Tat and thus provide an effective approach to protect neurons. Methods: We constructed a humanized anti-Tat Hutat2:Fc fusion protein with the goal of antagonizing HIV-1 Tat and delivered the gene into cell lines and primary human monocyte-derived macrophages (hMDM) by an HIV-based lentiviral vector. The function of the anti-Tat Hutat2:Fc fusion protein and the potential side effects of lentiviral vector-mediated gene transfer were evaluated in vitro. Results: Our study demonstrated that HIV-1-based lentiviral vector-mediated gene transduction resulted in a high-level, stable expression of anti-HIV-1 Tat Hutat2:Fc in human neuronal and monocytic cell lines, as well as in primary hMDM. Hutat2:Fc was detectable in both cells and supernatants and continued to accumulate to high levels within the supernatant. Hutat2:Fc protected mouse cortical neurons against HIV-1 Tat86-induced neurotoxicity. In addition, both secreted Hutat2:Fc and transduced hMDM led to reducing HIV-1BaL viral replication in human macrophages. Moreover, lentiviral vector-based gene introduction did not result in any significant changes in cytomorphology and cell viability. Although the expression of IL8, STAT1, and IDO1 genes was up-regulated in transduced hMDM, such alternation in gene expression did not affect the neuroprotective effect of Hutat2:Fc. Conclusions: Our study demonstrated that lentivirus-mediated gene transfer could efficiently deliver the Hutat2:Fc gene into primary hMDM and does not lead to any significant changes in hMDM immune-activation. The neuroprotective and HIV-1 suppressive effects produced by Hutat2:Fc were comparable to that of a full-length anti-Tat antibody. This study provides the foundation and insights for future research on the potential use of Hutat2:Fc as a novel gene therapy approach for HAND through utilizing monocytes/macrophages, which naturally cross the blood-brain barrier, for gene delivery. Electronic supplementary material The online version of this article (doi:10.1186/s12974-014-0195-2) contains supplementary material, which is available to authorized users

Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer

Therapeutic approaches aimed at curing prostate cancer are only partially successful given the occurrence of highly metastatic resistant phenotypes that frequently develop in response to therapies. Recently, we have described αvβ6, a surface receptor of the integrin family as a novel therapeutic target for prostate cancer; this epithelial-specific molecule is an ideal target since, unlike other integrins, it is found in different types of cancer but not in normal tissues. We describe a novel αvβ6-mediated signaling pathway that has profound effects on the microenvironment. We show that αvβ6 is transferred from cancer cells to monocytes, including β6-null monocytes, by exosomes and that monocytes from prostate cancer patients, but not from healthy volunteers, express αvβ6. Cancer cell exosomes, purified via density gradients, promote M2 polarization, whereas αvβ6 down-regulation in exosomes inhibits M2 polarization in recipient monocytes. Also, as evaluated by our proteomic analysis, αvβ6 down-regulation causes a significant increase in donor cancer cells, and their exosomes, of two molecules that have a tumor suppressive role, STAT1 and MX1/2. Finally, using the Ptenpc−/− prostate cancer mouse model, which carries a prostate epithelial-specific Pten deletion, we demonstrate that αvβ6 inhibition in vivo causes up-regulation of STAT1 in cancer cells. Our results provide evidence of a novel mechanism that regulates M2 polarization and prostate cancer progression through transfer of αvβ6 from cancer cells to monocytes through exosomes